Zentalis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing its lead product candidate, azenosertib (ZN-c3), for various oncology indications including ovarian cancer. As of November 4, 2026, the company had 98,265,863 shares of common stock outstanding and is prioritizing its Phase 3 ASPENOVA and Phase 2 DENALI trials.
Zentalis Pharmaceuticals reported third quarter 2026 financial results and provided updates on its clinical pipeline, specifically the azenosertib program for ovarian cancer. The company expects a topline readout from the DENALI trial in the first half of 2027 and reported a cash runway extending into the first half of 2028.
“Overall survival data from DENALI Part 1b presented at ESMO reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals
“With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer.”
Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals